Shore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) -

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
81
Shore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) - Vernalis Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Name of exempt principal trader: Shore Capital Stockbrokers Ltd
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree Vernalis Plc
(c) Name of the party to the offer with which exempt principal trader is connected: Vernalis Plc
(d) Date dealing undertaken: 14 June 2018
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? NO

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)        Purchases and sales

Class of relevant security Purchases/ sales   Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary Purchases 135086 7.06p 6.12p
Ordinary Sales 28165 6.62p 6.6p

(b)        Derivatives transactions (other than options)

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
           

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercising

Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
         

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"
  None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None  
Date of disclosure: 15 June 2018
Contact name: Oliver Eker
Telephone number: 0207 468 7992

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Ameripath USA Collaborates with Recovery Resolutions to Support Recovery Housing

Updated Category News Views 308

Ameripath USA's New Partnership for Recovery Housing Ameripath USA has formed a strategic partnership with Recovery Resolutions LLC to significantly improve access to high-quality Addiction Recovery Homes throughout the country. This collaboration merges Ameripath's extensive real estate expertise with Recovery Resolutions' impressive success model, boasting a 95% success...

Continue Reading
Finzly’s ISO 20022 Migration Readiness Sets Industry Standards

Updated Category News Views 311

Finzly’s Innovations in ISO 20022 Payment Standards Finzly is at the forefront of transforming how financial institutions manage payments through its state-of-the-art platform designed for modern banking needs. As the shift to SWIFT MX ISO 20022 continues, Finzly's clientele is emerging as early adopters, demonstrating a commitment to embracing new technologies that...

Continue Reading
Innovative Drug Delivery Solutions for Parkinson's Disease

Updated Category News Views 251

Serina Therapeutics' Approach to Parkinson's Disease Serina Therapeutics is at the forefront of developing new treatments for complex neurological disorders, particularly Parkinson’s disease. This progressive neurological disorder significantly impacts motor functions and quality of life for those affected. With innovative solutions on the horizon, Serina is prepared to...

Continue Reading
Waters Corporation Leader to Speak at HealthCONx Conference

Updated Category News Views 124

Waters Corporation to Participate in HealthCONx Conference Waters Corporation (NYSE: WAT), located in Milford, Massachusetts, is pleased to announce its participation in the upcoming HealthCONx Conference. Udit Batra, the President and Chief Executive Officer of Waters, will engage in an insightful fireside chat set for Wednesday, December 4th, 2024, at 10:00 AM Eastern...

Continue Reading
mRNA Synthesis and Manufacturing Market Expected to Grow Steadily

Updated Category News Views 33

Growing Insights into the mRNA Synthesis and Manufacturing Market The mRNA synthesis and manufacturing market is on a promising trajectory, with projections indicating substantial growth from USD 624.4 million to USD 738.3 million by 2029. This expansion translates into a compound annual growth rate (CAGR) of 3.4%. Several factors are propelling this growth, including an...

Continue Reading